

FIG. 1




FIG. 2




FIG. 3

A




FIG. 3 CONTINUED

B




FIG. 3 CONTINUED

C




FIG. 3 CONTINUED

D




FIG. 3 CONTINUED

E




FIG. 3 CONTINUED

mMRC-10 sum score : Boxplot of baseline (Safety Set)

F




FIG. 3 CONTINUED

G




FIG. 3 CONTINUED

H




FIG. 4

A




FIG. 4 CONTINUED





FIG. 4 CONTINUED




At Risk		18	16	15	13	12	12	12	12	12	12	10	9
EMPA IV 30/10 mg/kg		18	16	15	13	12	12	12	12	12	12	10	9
Placebo		9	8	8	6	4	4	3	3	2	2	2	1
Events		0	2	3	6	6	6	6	6	6	6	7	7
EMPA IV 30/10 mg/kg		0	2	3	6	6	6	6	6	6	6	7	7
Placebo		0	1	3	4	5	5	6	7	7	7	7	7

FIG. 4 CONTINUED

D

Time to Relapse during DBTP
Cohort2 Safety Analysis Set & paramcd == "RELAPSE"



At Risk

18 18 15 15 15 15 15 13 13 13 13 9

9 7 6 5 4 4 4 2 2 2 0

Events

0 2 3 3 3 4 4 5 5 5 5

0 3 4 4 5 6 7 7 8 8

FIG. 5

A




FIG. 5 CONTINUED




FIG. 6

A




FIG. 6 CONTINUED

B




FIG. 6 CONTINUED
C




FIG. 7
A




FIG. 7 CONTINUED

B




FIG. 7 CONTINUED




FIG. 8

A




FIG. 8 CONTINUED
B




FIG. 9




FIG. 9 CONTINUED

B




FIG. 10




FIG. 11





FIG. 11 CONTNUED

B

FSS: Average Score : Boxplot of change from baseline by treatment group at Last Assessment before IVIg and Last Assessment during treatment period (Safety Set)



EMPA IV 30/10 mg/kg EMPA IV 15/5 mg/kg PBO IV Co1 PBO IV Co2

FIG. 12.




FIG. 14




FIG. 14 CONTINUED

B




FIG 16.




FIG 17. Complement CH50 (mEq/mL)-Percent Change from DBTP Baseline: Median (IQR) (linear) versus time during treatment period by empasprubart dose (PD Set)

